Transimmune
Transimmune is dedicated to building immune cell therapies that harness the natural physiology of dendritic cells to reprogram immunity. Their mission is to cure diseases by reprogramming immunity using physiologic dendritic cells, with implications for targeted vaccination, cancer, viral targets, autoimmunity, and graft vs host disease. They have a rich history rooted in understanding and replicating the natural priming of immunity, with a focus on physiologic partnerships within the immune network. Their platform technology aims to improve in vivo potency and treatment pathways by producing dendritic cell products ex vivo in a rapid, point-of-care manner.
Industries
Nr. of Employees
small (1-50)
Transimmune
Products
Physiologic dendritic cell therapy program for immune stimulation
Autologous physiologically-activated dendritic cell program designed to induce antigen-specific immune activation for oncology and infectious disease indications.
Physiologic dendritic cell therapy program for immune tolerance
Autologous physiologically-activated dendritic cell program designed to induce immune dampening and tolerance for autoimmune disease and graft-versus-host disease indications.
Physiologic dendritic cell therapy program for immune stimulation
Autologous physiologically-activated dendritic cell program designed to induce antigen-specific immune activation for oncology and infectious disease indications.
Physiologic dendritic cell therapy program for immune tolerance
Autologous physiologically-activated dendritic cell program designed to induce immune dampening and tolerance for autoimmune disease and graft-versus-host disease indications.
Services
Joint research programs with academic and clinical centers for rapid prototyping, disease model access, and translational experiments.
Design and execution of preclinical studies to evaluate efficacy and mechanism of dendritic cell–based interventions in animal models.
Development of hardware and processing workflows to enable rapid ex vivo physiologic activation and generation of dendritic cell products.
Regulatory-focused preclinical and manufacturing studies to support investigational filings.
Joint research programs with academic and clinical centers for rapid prototyping, disease model access, and translational experiments.
Design and execution of preclinical studies to evaluate efficacy and mechanism of dendritic cell–based interventions in animal models.
Development of hardware and processing workflows to enable rapid ex vivo physiologic activation and generation of dendritic cell products.
Regulatory-focused preclinical and manufacturing studies to support investigational filings.
Expertise Areas
- Dendritic cell therapy development
- Point-of-care autologous cell manufacturing
- Immuno-oncology and vaccine development
- Translational research and academic collaboration
Key Technologies
- Physiologic ex vivo dendritic cell priming
- Platelet-activated monocyte-to-dendritic-cell differentiation
- Point-of-care autologous cell manufacturing
- mRNA vaccine combination strategies
News & Updates
Transimmune Secures $5m Funding to Enhance mRNA Vaccination with Novel Dendritic Cell Therapy
Transimmune selected for inaugural ARPA-H grant, alongside Emory University, Yale University and University Of Georgia.
May 2020 | OncoImmunology
March 2020 | Science Advances
July 2019 | Int Rev Cell Mol Biol.
Transimmune Secures $5m Funding to Enhance mRNA Vaccination with Novel Dendritic Cell Therapy
Transimmune selected for inaugural ARPA-H grant, alongside Emory University, Yale University and University Of Georgia.
May 2020 | OncoImmunology
March 2020 | Science Advances
July 2019 | Int Rev Cell Mol Biol.